| Budget Amount *help |
¥27,430,000 (Direct Cost: ¥21,100,000、Indirect Cost: ¥6,330,000)
Fiscal Year 2013: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2012: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2011: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
|
|---|
| Research Abstract |
We focused on the targeting to transferrin receptor, IL4 receptor alpha, Neuropilin-1, and Her2 which over-express on the refractory cancer cells including pancreatic cancer and glioblastoma, and designed hybrid peptide in which targeting peptides to these receptors were conjugated with lytic type peptide that disintegrates selectively cancer cell membrane. It was found that designed hybrid peptides had effective cytotoxic and anti-tumor activities toward cancer cells over-expressing these receptors including resistant cell lines to trastuzumab and lapatinib both in vitro and in vivo. Thus, it is suggested that hybrid peptide designed in this study may provide a potent therapeutic option for patients with refractory cancer in the future.
|
